Company intelligence / Profile preview
MediLink Therapeutics
Suzhou, Jiangsu, China
- Ownership
- Private
- Employees
- ~34
- Development stage
- Phase 3
01
Overview
MediLink has advanced several proprietary ADC candidates into clinical development. Notably, YL201 has received orphan drug designation from the FDA and launched a Phase I/II study. HBM9033/YL215, targeting mesothelin for solid tumors, was developed with Nona Biosciences using the TMALIN® platform; it demonstrated superior potency/safety preclinically and received FDA IND clearance in August 2023. A BioNTech-partnered asset faced an FDA hold due to safety concerns at higher doses during a US trial. The company continues to expand its pipeline through internal R&D and major outlicensing deals.
- Therapeutic areas
- OtherOncology
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs, via partnerships)
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
BioNTech – multi-target TMALIN® ADC license agreement ($1B+ deal value reported); partnered asset currently on partial clinical hold by FDA due to safety concerns at high dose levels during US trial enrollmentPfizer – sublicensee of HBM9033/YL215 via Nona Biosciences partnership; MediLink receives sub-license payments from this collaborationRoche – collaboration on YL211 programZai Lab – collaboration on YL212Harbour BioMed/Nona Biosciences – co-development of HBM9033/YL215 using Harbour Mice® antibody discovery platform
Beyond the preview
Go deeper on MediLink Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MediLink Therapeutics.